Global Mycoplasma Testing Kits amp Reagents Market Size By Type (PCR Assays, Nucleic Acid Detection Kits), By Application (Academic Research Institutes, Cell Banks), By Region, And Segment Forecasts,...

lobal Mycoplasma Testing Kits & Reagents Market Report Description

The Global Mycoplasma Testing Kits & Reagents Market was valued at USD 930 million in 2023 and is projected to surpass USD 1.85 billion by 2031, growing at a CAGR of 9.0% during the forecast period of 2023–2031. This market is witnessing strong growth due to the rising prevalence of cell culture contamination, growing adoption of biologics and biosimilars, and stringent regulatory requirements for biopharmaceutical production. Mycoplasma contamination, being one of the most common and undetectable microbial contaminants in cell cultures, has heightened the demand for sensitive and rapid testing methods, further boosting the demand for effective kits and reagents.

Drivers

1. Increasing Biopharmaceutical R&D Investments:

Rising investments in biopharmaceutical R&D are driving demand for contamination-free cultures, intensifying the need for reliable mycoplasma detection kits across research and manufacturing labs.

2. Regulatory Emphasis on Quality Control:

Regulatory authorities such as the FDA and EMA mandate routine mycoplasma testing for cell lines used in biologics production, significantly bolstering market growth.

3. Technological Advancements in Detection Methods:

Innovations in PCR-based and nucleic acid amplification technologies have improved test sensitivity, speed, and automation, increasing adoption among end-users.

Restraints

1. High Cost of Advanced Testing Kits:

The high cost of modern PCR-based and enzymatic detection kits may limit accessibility, especially for small- to mid-sized laboratories in developing economies.

2. Limited Awareness in Low-Income Countries:

A lack of awareness regarding the implications of mycoplasma contamination continues to hinder market penetration in certain regions.

Opportunity

1. Expanding Cell Therapy and Vaccine Manufacturing:

As the demand for vaccines, gene therapies, and regenerative medicines surges globally, so does the requirement for stringent quality control, creating lucrative opportunities for mycoplasma testing solutions.

2. Growing Presence of CROs and CDMOs:

The rising trend of outsourcing drug development processes to CROs and CDMOs is expected to significantly drive the adoption of mycoplasma testing kits to ensure contamination-free workflows.

Market by System Type Insights

Among system types, the PCR-based Mycoplasma Testing Kits segment accounted for the largest market share in 2023. These kits are preferred due to their high specificity, sensitivity, and faster turnaround times. However, the Enzymatic Detection Kits segment is anticipated to grow at the fastest rate due to ease of use and cost-effectiveness for routine screenings.

Market by End-use Insights

Based on end-use, the Pharmaceutical & Biotechnology Companies segment held the dominant share in 2023, driven by the increasing need for rigorous contamination testing in the manufacturing of biologics. The Academic & Research Institutions segment is also projected to grow significantly due to increased investments in life science research.

Market by Regional Insights

Geographically, North America led the market in 2023, supported by a strong biopharmaceutical industry and stringent regulatory standards. Meanwhile, the Asia-Pacific region is forecasted to exhibit the highest CAGR during the forecast period, attributed to increasing biologics manufacturing, growing R&D expenditure, and rising adoption of advanced cell culture technologies in countries like China, India, and South Korea.

Competitive Scenario

Leading companies in the global mycoplasma testing kits & reagents market include Thermo Fisher Scientific, Lonza Group, Merck KGaA, Sartorius AG, Bio-Rad Laboratories, PromoCell GmbH, Charles River Laboratories, and Minerva Biolabs GmbH. These players are focusing on strategic partnerships, product innovation, and geographical expansion.

Key Developments:

In 2023, Thermo Fisher Scientific introduced a next-generation PCR-based mycoplasma detection kit featuring integrated sample prep and automation.

In 2024, Merck KGaA expanded its portfolio with ready-to-use mycoplasma reagent kits targeting small-scale cell culture labs.

In 2025, Lonza partnered with a major Asian CDMO to provide rapid mycoplasma detection systems across GMP facilities.

Scope of Work – Global Mycoplasma Testing Kits & Reagents Market

Report Metric Details

Market Size (2023) USD 930 million

Projected Market Size (2031) USD 1.85 billion

CAGR (2023–2031) 9.0%

Market Segments System Type (PCR-based, Enzymatic), End-use, Region

Growth Drivers Rising R&D in biologics, regulatory compliance

Opportunities Growth in cell therapy, outsourcing to CROs/CDMOs

FAQs

1) What is the current market size of the Global Mycoplasma Testing Kits & Reagents Market?

The market was valued at USD 930 million in 2023.

2) What is the major growth driver of the Global Mycoplasma Testing Kits & Reagents Market?

The primary growth driver is the rising R&D activity in biologics and stringent regulatory standards for contamination control.

3) Which is the largest region during the forecast period in the Global Mycoplasma Testing Kits & Reagents Market?

North America is the largest region due to a robust pharmaceutical sector and strict regulatory landscape.

4) Which segment accounted for the largest market share in Global Mycoplasma Testing Kits & Reagents Market?

PCR-based Mycoplasma Testing Kits dominated the market in 2023.

5) Who are the key market players in the Global Mycoplasma Testing Kits & Reagents Market?

Key players include Thermo Fisher Scientific, Lonza Group, Merck KGaA, Sartorius AG, and Bio-Rad Laboratories.

Would you like a visual summary or PowerPoint slide of this report?